| 前收市價 | 4.88 |
| 開市 | 4.87 |
| 買盤 | 4.99 x 200 |
| 賣出價 | 5.04 x 400 |
| 今日波幅 | 4.87 - 5.11 |
| 52 週波幅 | 2.13 - 7.73 |
| 成交量 | |
| 平均成交量 | 578,890 |
| 市值 | 242M |
| Beta 值 (5 年，每月) | 1.31 |
| 市盈率 (最近 12 個月) | 11.16 |
| 每股盈利 (最近 12 個月) | 0.45 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 4.33 |
ZacksWhat's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
ZacksPuma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZacksFDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
